Article info
PDFClinical trial
ADAGIO: a phase IIb international study of the Wee1 inhibitor adavosertib in women with recurrent or persistent uterine serous carcinoma
- Correspondence to Dr Joyce Liu, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; joyce_liu{at}dfci.harvard.edu
Citation
ADAGIO: a phase IIb international study of the Wee1 inhibitor adavosertib in women with recurrent or persistent uterine serous carcinoma
Publication history
- Accepted October 13, 2021
- First published October 29, 2021.
Online issue publication
November 15, 2022
Article Versions
- Previous version (10 January 2022).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ.